1. Medtech Insight
  2. >>Archive

US approval for Stanmore's JTS non-invasive extendible implant

 
• By Elizabeth Cairns

The Juvenile Tumour System (JTS), a femoral replacement implant developed by Stanmore Implants, has received US FDA 510(k) approval. The non-invasive extendible distal femoral replacement device may now be used in paediatric orthopaedic oncology surgery in the US. The JTS implant is used to replace large sections of the distal femur that have been removed during surgery, often to treat cancer. It uses an electromagnetic device in order to lengthen the prosthesis without the need for surgery or sedation; previously patients had to undergo multiple, painful surgeries in order to lengthen their implants as they grew. Over 240 of the devices have been implanted in 15 countries worldwide. It costs $267 to undertake a non-invasive lengthening procedure, compared with around $8,000 if surgery is required, Stanmore says. The product will be launched in the US "during the next few months".

The Juvenile Tumour System (JTS), a femoral replacement implant developed by Stanmore Implants, has received US FDA 510(k) approval. The non-invasive extendible distal femoral replacement device may now be used in paediatric orthopaedic oncology surgery in the US. The JTS implant is used to replace large sections of the distal femur that have been removed during surgery, often to treat cancer. It uses an electromagnetic device in order to lengthen the prosthesis without the need for surgery or sedation; previously patients had to undergo multiple, painful surgeries in order to lengthen their implants as they grew. Over 240 of the devices have been implanted in 15 countries worldwide. It costs $267 to undertake a non-invasive lengthening procedure, compared with around $8,000 if surgery is required, Stanmore says. The product will be launched in the US "during the next few months".

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By Elizabeth Orr

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

 
• By Amanda Maxwell

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.